Analyzing Cerus Corporation (CERS) and Trivascular Technologies (NASDAQ:TRIV)
Cerus Corporation (NASDAQ: CERS) and Trivascular Technologies (NASDAQ:TRIV) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, risk, valuation, profitability, analyst recommendations, earnings and dividends.
Insider and Institutional Ownership
65.1% of Cerus Corporation shares are held by institutional investors. 7.4% of Cerus Corporation shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
This is a breakdown of current ratings and recommmendations for Cerus Corporation and Trivascular Technologies, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Cerus Corporation currently has a consensus target price of $7.25, indicating a potential upside of 191.16%. Given Cerus Corporation’s higher probable upside, equities research analysts clearly believe Cerus Corporation is more favorable than Trivascular Technologies.
Valuation & Earnings
This table compares Cerus Corporation and Trivascular Technologies’ revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|Cerus Corporation||$36.83 million||7.03||-$61.75 million||($0.61)||-4.08|
Trivascular Technologies has higher revenue, but lower earnings than Cerus Corporation.
This table compares Cerus Corporation and Trivascular Technologies’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Cerus Corporation beats Trivascular Technologies on 7 of the 8 factors compared between the two stocks.
Cerus Corporation Company Profile
Cerus Corporation is a biomedical products company. The Company is engaged in developing and commercializing the INTERCEPT Blood System for blood safety. The Company operates through blood safety segment. The Company’s INTERCEPT Blood System is based on its technology for controlling biological replication, and is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The Company’s INTERCEPT Blood System is designed to target and inactivate blood-borne pathogens, such as viruses, including human immunodeficiency virus (HIV), West Nile, Severe acute respiratory syndrome (SARS), hepatitis B and C; bacteria and parasites, as well as harmful white blood cells, while preserving the therapeutic properties of platelet, plasma and red blood cell transfusion products. The Company’s INTERCEPT Blood System is for use with blood components, including plasma, platelets, and red blood cells.
Trivascular Technologies Company Profile
Trivascular Technologies, Inc. is a medical device company developing and commercializing technologies to advance minimally invasive treatment of abdominal aortic aneurysms (AAA). The Ovation System, the Company’s solution for the treatment of AAA through minimally invasive endovascular aortic repair, or EVAR, is a stent graft platform, providing an alternative to conventional devices. It is designed to specifically address many of the limitations associated with conventional EVAR devices and expand the pool of patients eligible for EVAR. The Company is developing Ovation iX iliac limbs for use with both its Ovation Prime and its Ovation iX and Alto aortic bodies, which are in development. Trivascular is developing Ovation iX aortic bodies for use with both its Ovation Prime and its Ovation iX iliac limbs. The Company is developing an aortic body that together with the iliac limbs makes up the Ovation Alto stent graft.
Receive News & Ratings for Cerus Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cerus Corporation and related companies with MarketBeat.com's FREE daily email newsletter.